This company has been marked as potentially delisted and may not be actively trading. ChemoCentryx (CCXI) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock CCXI Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period BeiGene Enters Sublease Agreement with ChemoCentryx for ExpansionJanuary 20, 2025 | tipranks.comRishi Gupta's Net WorthFebruary 22, 2024 | benzinga.comChemoCentryx (NASDAQ:CCXI) Now Covered by Analysts at StockNews.comDecember 4, 2022 | marketbeat.comChemoCentryx, Inc. (NASDAQ:CCXI) Receives Consensus Rating of "Hold" from AnalystsShares of ChemoCentryx, Inc. (NASDAQ:CCXI - Get Rating) have earned an average rating of "Hold" from the six ratings firms that are presently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating on the compNovember 28, 2022 | marketbeat.comAMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX - PR NewswireOctober 20, 2022 | prnewswire.comAMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYXOctober 20, 2022 | finance.yahoo.comTrading was temporarily halted for "CCXI" at 07:10 PM with a stated reason of "News pending."October 20, 2022 | marketbeat.comChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings - Yahoo FinanceOctober 17, 2022 | finance.yahoo.comChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual MeetingsOctober 17, 2022 | finance.yahoo.comChemoCentryx Inc Shares Close in on 52-Week High - Market Mover - NasdaqOctober 15, 2022 | nasdaq.comChemoCentryx, Inc. (NASDAQ:CCXI) Given Consensus Rating of "Hold" by BrokeragesChemoCentryx, Inc. (NASDAQ:CCXI - Get Rating) has been assigned an average recommendation of "Hold" from the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold recommendation, one has assigned a buy recomOctober 9, 2022 | marketbeat.comChemoCentryx Inc Shares Approach 52-Week High - Market Mover - NasdaqOctober 7, 2022 | nasdaq.comIs ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year? - NasdaqOctober 6, 2022 | nasdaq.comIs ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?October 6, 2022 | finance.yahoo.comChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewswireOctober 5, 2022 | globenewswire.comChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual MeetingOctober 5, 2022 | finance.yahoo.comChemoCentryx (NASDAQ: CCXI)September 30, 2022 | fool.comBiotech Valuations Remain In a Slump - TheStreetSeptember 24, 2022 | thestreet.comAmgen CEO Sees Tougher Sleddin - GuruFocus.comSeptember 19, 2022 | gurufocus.comThese 10 Biotech Stocks Would Have Netted You $10000 More This Year - Investor's Business DailySeptember 19, 2022 | investors.comSPDR S&P Biotech ETF Experiences Big Inflow - NasdaqSeptember 15, 2022 | nasdaq.comAmgen (AMGN): Growing Doubts About The Future - Seeking AlphaSeptember 14, 2022 | seekingalpha.comChemoCentryx, Inc. (NASDAQ:CCXI) Receives Consensus Rating of "Hold" from BrokeragesChemoCentryx, Inc. (NASDAQ:CCXI - Get Rating) has earned a consensus rating of "Hold" from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy ratiSeptember 14, 2022 | marketbeat.com2022-09-13 | NDAQ:CCXI | Press Release | ChemoCentryx Inc. - StockhouseSeptember 13, 2022 | stockhouse.comINVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.'s Directors and Officers for Breach of Fiduciary Duties – CCXI - Business WireSeptember 13, 2022 | businesswire.comChemoCentryx (NASDAQ:CCXI) – INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCent - BenzingaSeptember 13, 2022 | benzinga.comAmgen Stock Is Looking Interesting On The Dip (NASDAQ:AMGN) - Seeking AlphaSeptember 13, 2022 | seekingalpha.comWhy Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report? - NasdaqSeptember 7, 2022 | nasdaq.comWhy Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?September 7, 2022 | finance.yahoo.comCCXI.N - ChemoCentryx Inc | Stock Price & Latest News | ReutersSeptember 5, 2022 | reuters.comCCXI.O - ChemoCentryx Inc | Stock Price & Latest News | ReutersSeptember 4, 2022 | reuters.comChemocentryx (CCXI) – ChemoCentryx's Return On Capital Employed Insights - BenzingaSeptember 1, 2022 | benzinga.comAerie Pharmaceuticals (AERI), Chemocentryx (CCXI) – SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates CCX - BenzingaAugust 31, 2022 | benzinga.comChemoCentryx, Inc. (NASDAQ:CCXI) Sees Significant Increase in Short InterestChemoCentryx, Inc. (NASDAQ:CCXI - Get Rating) was the recipient of a large increase in short interest in the month of August. As of August 15th, there was short interest totalling 6,910,000 shares, an increase of 6.1% from the July 31st total of 6,510,000 shares. Based on an average trading volume of 2,240,000 shares, the days-to-cover ratio is currently 3.1 days. Approximately 11.9% of the company's shares are sold short.August 31, 2022 | marketbeat.comChemocentryx (CCXI) – INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, In - BenzingaAugust 31, 2022 | benzinga.comAmgen (AMGN) Outperforms Industry Year to Date: What's Next? - NasdaqAugust 30, 2022 | nasdaq.com2022-08-30 | NDAQ:CCXI | Press Release | ChemoCentryx Inc. - StockhouseAugust 30, 2022 | stockhouse.comBiotech Stocks: These 10 Have A 40% Gain This Year (And Nothing To Do With Covid) - Investor's Business DailyAugust 29, 2022 | investors.com2022-08-25 | NDAQ:CCXI | Press Release | ChemoCentryx Inc. - StockhouseAugust 25, 2022 | stockhouse.com2022-08-24 | NDAQ:CCXI | Press Release | ChemoCentryx Inc. - StockhouseAugust 24, 2022 | stockhouse.comChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical ConferencesAugust 24, 2022 | finance.yahoo.com3 Biopharmas on Buyout Watch - The Motley FoolAugust 22, 2022 | fool.comSHAREHOLDER ALERT: Weiss Law Reminds CCXI, HNGR, U, and IRBT Shareholders About Its Ongoing Investigations - PR NewswireAugust 18, 2022 | prnewswire.comMergers Rebound. Here's Who Will Benefit. - Barron'sAugust 18, 2022 | barrons.comChemoCentryx (CCXI) Now Trades Above Golden Cross: Time to Buy? - NasdaqAugust 18, 2022 | nasdaq.comHere's Why ChemoCentryx (CCXI) is a Great Momentum Stock to Buy - Yahoo FinanceAugust 17, 2022 | finance.yahoo.comHere's Why ChemoCentryx (CCXI) is a Great Momentum Stock to Buy - NasdaqAugust 16, 2022 | nasdaq.comChemoCentryx (CCXI) Now Trades Above Golden Cross: Time to Buy? - Yahoo FinanceAugust 16, 2022 | finance.yahoo.comChemoCentryx (CCXI) Now Trades Above Golden Cross: Time to Buy?August 16, 2022 | finance.yahoo.comHere's Why ChemoCentryx (CCXI) is a Great Momentum Stock to BuyAugust 16, 2022 | finance.yahoo.com Get ChemoCentryx News Delivered to You Automatically Sign up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter. Email Address CCXI Media Mentions By Week CCXI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CCXI News Sentiment▼0.191.03▲Average Medical News Sentiment CCXI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CCXI Articles This Week▼00▲CCXI Articles Average Week Get ChemoCentryx News Delivered to You Automatically Sign up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies United Therapeutics News Today Incyte News Today Neurocrine Biosciences News Today Exelixis News Today BioMarin Pharmaceutical News Today Exact Sciences News Today Halozyme Therapeutics News Today Repligen News Today Madrigal Pharmaceuticals News Today Ionis Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CCXI) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | SponsoredDollar Collapse Warning: Protect Your Wealth NOWGlobal central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Ame...Lear Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ChemoCentryx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ChemoCentryx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CCXI Stock Free CCXI Stock Alerts